Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus

Gene Therapy

Volumn 22, Issue 1, 2015, Pages 104-110

  Wang, S ^a   Olumolade, O O ^a   Sun, T ^a   Samiotaki, G ^a   Konofagou, E E ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ECHO CONTRAST MEDIUM; SYNAPSIN;

ADENO ASSOCIATED VIRUS; ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CRANIOTOMY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SELECTIVITY; FEASIBILITY STUDY; FOCUSED ULTRASOUND; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFECTION RISK; MICROBUBBLE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; ULTRASOUND; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ANIMAL; CAUDATE NUCLEUS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NERVE CELL; PHYSIOLOGY; PROCEDURES; VASCULARIZATION;

ADENO-ASSOCIATED VIRUS;

ANIMALS; BLOOD-BRAIN BARRIER; CAUDATE NUCLEUS; DEPENDOVIRUS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; MICE; MICROBUBBLES; NEURONS; SONICATION; TRANSDUCTION, GENETIC;

EID: 84920514770     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.91     Document Type: Article

References (32)

1. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord 2013; 28: 24-30.
2. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. Biosci Rep 2001; 21: 691-710.
3. Chtarto A, Bockstael O, Tshibangu T, Dewitte O, Levivier M, Tenenbaum L. A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol 2013; 76: 217-232.
4. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73: 1662-1669.
5. LeWitt Pa, Rezai AR, Leehey Ma, Ojemann SG, Flaherty AW, Eskandar EN et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10: 309-319.
6. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013; 80: 1698-1701.
7. Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13: 1391-1412.
8. Mann JD, Butler AB, Rosenthal JE, Maffeo CJ, Johnson RN, Bass NH. Regulation of intracranial pressure in rat, dog, and man. Ann Neurol 1978; 3: 156-165.
9. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convectionenhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080.
10. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013; 36: 437-449.
11. Hynynen K, McDannold N, Sheikov Na, Jolesz Fa, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005; 24: 12-20.
12. Choi JJ, Selert K, Vlachos F, Wong A, Konofagou EE. Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles. Proc Natl Acad Sci USA 2011; 108: 16539-16544.
13. McDannold N, Vykhodtseva N, Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys Med Biol 2006; 51: 793-807.
14. Tung Y-S, Marquet F, Teichert T, Ferrera V, Konofagou EE. Feasibility of noninvasive cavitation-guided blood-brain barrier opening using focused ultrasound and microbubbles in nonhuman primates. Appl Phys Lett 2011; 98: 163704.
15. Baseri B, Choi JJ, Deffieux T, Samiotaki G, Tung Y-S, Olumolade O et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles. Phys Med Biol 2012; 57: N65-N81.
16. Jordaõ JF, Thévenot E, Markham-Coultes K, Scarcelli T, Weng Y-Q, Xhima K et al. Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol 2013; 1-14.
17. Park E-J, Zhang Y-Z, Vykhodtseva N, McDannold N. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release 2012; 163: 277-284.
18. Thévenot E, Jordaõ JF, O'Reilly MA, Markham K, Weng Y-Q, Foust KD et al. Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum Gene Ther 2012; 23: 1144-1155.
19. Alonso A, Reinz E, Leuchs B, Kleinschmidt J, Fatar M, Geers B et al. Focal delivery of AAV2/1-transgenes into the rat brain by localized ultrasound-induced BBB opening. Mol Ther Nucleic Acids 2013; 2: e73.
20. Hsu P-H, Wei K-C, Huang C-Y, Wen C-J, Yen T-C, Liu C-L et al. Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound. PLoS One 2013; 8: e57682.
21. Kügler S, Kilic E, Bähr M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther 2003; 10: 337-347.
22. Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, Beyer J et al. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther 2012; 23: 891-902.
23. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105.
24. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci 2009; 10: 519-529.
25. Brady ML, Raghavan R, Singh D, Anand PJ, Fleisher AS, Mata J et al. In vivo performance of a microfabricated catheter for intraparenchymal delivery. J Neurosci Methods 2014; 229: 76-83.
26. Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS et al. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg 2013; 91: 92-103.
27. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 2012; 72: 3652-3663.
28. Downs ME, Buch A, Wu S-Y, Sierra C, Karakatsani M, Chen S et al. Safety of long term chronic blood brain barrier opening via microbubble enhanced focused ultrasound in non-human primates. Fourth International Focused Ultrasound Symposium; 12-16 October; Washington, DC, 2014.
29. Wang S, Samiotaki G, Olumolade O, Feshitan JA, Konofaqou EE. Microbubble type and distribution dependence of focused ultrasound-induced blood-brain barrier opening. Ultrsound Med Biol 2013; 40: 1-8.
30. Tung Y-S, Vlachos F, Feshitan JA, Borden MA, Konofagou EE. The mechanism of interaction between focused ultrasound and microbubbles in blood-brain barrier opening in mice. J Acoust Soc Am 2011; 130: 3059-3067.
31. Choi JJ, Pernot M, Brown TR, Small SA, Konofagou EE. Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. Phys Med Biol 2007; 52: 5509-5530.
32. Vlachos F, Tung Y-S, Konofagou EE. Permeability assessment of the focused ultrasound-induced blood-brain barrier opening using dynamic contrastenhanced MRI. Phys Med Biol 2010; 55: 5451-5466.